Skip to main content

Table 4 Between-group analysis and within-group analysis of outcomes assessed at follow up after 13–18 months

From: Resistance exercise improves muscle strength, health status and pain intensity in fibromyalgia—a randomized controlled trial

Measures Resistance exercise (experimental) Relaxation therapy (control) Between group analysis for change
Baseline 13–18 month follow up Follow up- baseline Within-group analysis Baseline 13–18 month follow up Follow up-baseline Within-group analysis
(n = 67) (n = 48) (n = 48) (n = 63) (n = 43) (n = 43)
Mean (SD) Mean (SD) Δ (SD) p value Mean (SD) Mean (SD) Δ (SD) p value p value
Median (min; max) Median (min; max) Δ (min; max)   Median (min; max) Median (min; max) Δ (min; max)
Secondary outcomes
FIQ total, 0–100 60.5 (14.4) 57.1 (19.4) −1.8 (17.0) 0.71 61.1 (17.3) 55.4 (17.0) −3.4 (12.3) 0.065 0.35
59 (31; 95) 59 (17; 92) 1 (−45; 35) 61 (17; 88) 55 (15; 90) −3 (−28; 36)
Current pain intensity, VAS 49.3 (23.9) 49.2 (20.8) 0.7 (23.4) 0.87 52.4 (18.3) 52.1 (19.5) −2.9 (19.6) 0.45 0.52
50 (5; 100) 47 (9; 84) 3 (−73; 58) 51 (10; 88) 53 (5; 83) −2 (−62; 46)
SF36 PCS, 0–100 31.2 (7.9) 32.2 (8.0) 0.8 (7.1) 0.39 29.9 (8.1) 32.0 (9.4) 1.9 (7.3) 0.16 0.62
31 (12; 50) 30 (17; 54) 1 (−14; 14) 30 (10; 49) 32 (17; 52) 1 (−13; 19)
SF36 MCS, 0–100 37.7 (12.2) 39.2 (13.9) −0.4 (13.5) 0.78 39.6 (12.1) 40.0 (11.9) −0.4 (12.2) 0.66 0.89
37 (10; 61) 39 (10; 59) 0 (−28; 29) 42 (16; 59) 43 (19; 60) −2 (−23; 28)
PDI, 0–70 35.3 (12.2) 33.0 (11.6) −2.6 (9.7) 0.094 35.0 (12.5) 33.7 (10.9) −0.3 (10.1) 0.58 0.42
36 (8; 69) 34 (7; 62) −3 (−28; 17) 34 (7; 61) 35 (8; 54) −1 (−21; 25)
CPAQ total, 0–120 63.6 (16.1) 68.0 (15.4) 3.6 (11.3) 0.044 62.4 (17.1) 66.6 (17.1) 2.3 (14.0) 0.21 0.76
63 (19; 106) 70 (33; 100) 3 (−21; 32) 61 (15; 107) 63 (24; 101) 1 (−35; 28)
FABQphysical, 0–24 9.7 (6.1) 10.1 (5.2) −0.1 (5.5) 0.57 11.2 (6.1) 9.7 (6.3) −1.6 (4.5) 0.051 0.38
9 (0; 24) 10 (2; 21) 0 (−10; 17) 11 (0; 24) 10 (0; 24) −1 (−14; 5)
FABQwork, 0–42 17.2 (12.7) 15.5 (11.5) −1.8 (9.7) 0.20 15.9 (12.1) 14.7 (12.4) −1.0 (11.2) 0.66 0.59
16 (0; 42) 14 (0; 41) −1 (−30; 32) 12 (0; 42) 13 (0; 42) 0 (−41; 30)
  1. Missing values at baseline: Resistance exercise group, SF36 PCS and SF36 MCS, n = 1; FABQwork, n = 6; FABQphysical, n = 1. Relaxation therapy group, CPAQ, n = 1; FABQwork, n = 8. Missing values at 13–18 month follow up, Resistance exercise group, current pain intensity, n = 2; FABQwork, n = 5; SF36 PCS and SF36 MCS, n = 1. Relaxation therapy group, FABQwork, n = 7; FABQphysical, n = 1; SF36 PCS and SF36 MCS, n = 1. Significant p values are shown in bold text. FIQ fibromyalgia impact questionnaire, VAS visual analog scale, SF36 short-form 36, PDI pain disability index, CPAQ chronic pain acceptance questionnaire, FABQ fear avoidance beliefs questionnaire